Replies to post #229941 on $Pistol Pete$, $Mick$ & Friends Stock Picks /news,

[mick]

GREAT READ PETER, $PFE

[mick]

$pfe is da one !!!!!

[mick]

good morning peter & all have great trading day 02-23-2021

[mick]

checkout $ride

[mick]

MAYBE TIME FOR $PFE & $BNTX

[mick]

also deep freeze toned down $PFE Pfizer vaccine

$PFE Pfizer vaccine gets final OK in Japan, with rollout to begin this week

https://www.japantimes.co.jp/?post_type=news&p=2920118

[mick]

good morning, 02-26-2021 last day of trading for feb.2021

[mick]

JNJ NOW O.K. FOR VACCINE F.D.A. STUFF

[mick]

trading halts 02/26/2021 09:30:00
AXCG
Eyes on the Go, Inc. Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
BBDA
BEBIDA BEVERAGE CO Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
BLSP
Blue Sphere Corp. Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
DKGR
Universal Apparel & Textile Company Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
EHOS
Ehouse Global, Inc. Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
EVTI
Eventure Interactive, Inc. Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
GYOG
Green Energy Enterprises, Inc. Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
HLXW
Helix Wind, Corp. Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
IPWG
International Power Group Ltd Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
MEDT
MediaTechnics Corporation Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
MRIB
Marani Brands, Inc. Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
NTLK
Net Talk.com Inc Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
PTAH
PTA Holdings Inc Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
PTTN
Patten Energy Solutions Group, Inc. Common Stock
H10
Other OTC
Halt
Yes
02/26/2021 09:30:00
WOFA
Wisdom Homes of America, Inc. Common Stock
H10
Other OTC
Halt
Yes

[mick]

good afternoon, 02-27-2021

[mick]

YES I ADDED MORE FOR WORTH EXCERPT is dis worth ah purchase to buy more $AABB 1 FOR 50 SHARE DIVY !!!!!

SO MGMT IS TRYING TO KEEP STRONG HANDS IN $AABB WITH DATES FAR OUT !!!!!

SMART !!!!! huge divy imho !!!!!

Asia Broadband Approves Stock Dividend For Shareholders

$AABB 1 SHARE COUNT [HEAVY] FOR EVERY 50 WOW DAT WOULD BE INTERESTING MY FRIEND


'Asia Broadband, Inc. (AABB)'

100='S 2 SHARES
1,000='20
10,000'S=200
100,00'S=2,000
1,000.000'S=20,000
2,000,000'S=40,000
3,000,000'S=60,000
4,000,000'S=80,000
5,000,000'S=100,000

by mgmt doing dis i think clears up some on shares .....
i think they would have to have shares in treasury or create some ?????
or ah buyback !!!!!

$AABB $5 ah share,nothing has changed wit $52 million in cash & 30 million in bullion

it is in $AABB $AABBG treasury vault.

so what is their worth ?????

$52 mil cash
$30 mil bullion
$10 mil.new mining investment
$$$$$ gold , silver , rare earth elements mexico has'em

and again someone could be looking @ $AABB $AABBG to buy'em out ?????

@ least $5.00 per share imho !!!!!

https://marketwirenews.com/news-releases/asia-broadband-approves-stock-dividend-for-sharehold-8845940050787848.html

Quote:
LAS VEGAS, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC : AABB)
is pleased to announce that the Company’s management and Board of Directors have approved a stock dividend.

The restricted common share dividend will be distributed on the basis
of 1 dividend share for every 50 shares owned to shareholders of record of the Company on April 5, 2021.

AABB would like to reward its loyal shareholder base for their patience, continued support and interest in sharing the success and growth of the Company.

AABB has recently experienced a tremendous increase in public communications with the Company,

particularly as a result of the development and upcoming release of
the AABB Gold (AABBG) cryptocurrency token.

Therefore, AABB is currently retaining a large investor relation’s agency that has the capacity and integrated services necessary to satisfy the Company’s public communications demands and awareness needs.

The new investor relations firm is expected to start providing
services for the Company in the next several days and we would ask
for your patience until that time.

AABB would also like to thank Integrity Media Inc. for their diligent,

professional and thorough services that they provided for the Company over the past month.

[mick]

solar Tesla’s Secret Model Y

[mick]

good morning happy sunday & to all have great wkend

[mick]

APS TO $TSLA PART TWO, OWNER TO BE ABLE TO RENT OUT THEIR E.V. YES RENT OUT

E.V. WHILE AT WORK ETC.

$TSLA MUSK He revolutionized online payment processing with PayPal...

He is revolutionizing space exploration with SpaceX...

He's revolutionizing the auto industry with Tesla...

And now Elon Musk is getting ready to unveil his next big project.

S.A.V. will change everything... and make a lot of people rich.

It could even put up to an extra $30,000 in your pocket every year.

https://secure.brownstoneresearch.com/?cid=MKT512132&eid=MKT523161&assetId=AST166320&page=1

[DewmBoom]

Why $SIRC:

a. Solar Roofing & Energy Storage ENABLER with boots on the ground
b. $TSLA certified Installer w Aero & Saint-Gobain
c. EV charging ENALER for the whole industry
d. Expanding US wide through acquisition
e. Seasoned & well connected management
f. Audited F coming soon

[mick]

GOOD EVENING PETER 03-02-2021

[mick]

COULD HAVE GIANT LEGS GROWING i'd say $MIKP IS READY MY FRIEND NEWS TODAY FOR AH KINDA RESTRICTED SHARES TO GET

[PENNIEStoSTACKS]

.0035 INTERNATIONAL PHARMACEUTICAL COMPANY +

Checkout the Hammer Candle at the bottom of this post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162280670

[stock1ace1]

RAND Earnings mon. 650k float big accumulation look https://schrts.co/tUfJUfQX

[stock1ace1]

I sent you rand look at the accumilation levels https://schrts.co/tUfJUfQX

650k float
2 mill o/s
Positive past earnings
Dividends

Solid company

[mick]

Pfizer Inc (PFE)
34.41 ? 0.21 (0.61%)
Volume: 30,506,954 @03/05/21 4:21:14 PM EST
Bid Ask Day's Range
- - 33.955 - 34.55
PFE Detailed Quote

[mick]

good afternoon peter

[mick]

$PFE got big time problem maybe ah suit against them from $BNTX [IS DA COMPANY]

i wonder why $PFE said got it covered to expand $BNTX PRODUCT ?????

BioNTech Recruits Rivals to Boost Covid-19 Vaccine Production
March 13 2021 - 08:29AM
Dow Jones News
By Bojan Pancevski

https://ih.advfn.com/stock-market/NASDAQ/sanofi-SNY/stock-news/84571512/biontech-recruits-rivals-to-boost-covid-19-vaccine

The maker of the West's first Covid-19 vaccine is building a new manufacturing alliance that could throw Europe and the rest of the
world a lifeline amid a painful shortage of shots and a rebound in infections.

BioNTech SE, a German company that joined with Pfizer Inc.
to manufacture and distribute its vaccine,
has marshaled an alliance of 13 companies,
including Novartis AG, Merck KGaA and Sanofi SA,
in an effort to meet -- and perhaps exceed --
an ambitious target of making two billion doses of vaccine this year.

The European Union has been struggling with a shortage of vaccines
as manufacturers,
including British-Swedish pharmaceutical firm AstraZeneca PLC,
have fallen behind on their delivery pledges to the bloc.

The shortage has largely been limited to the EU,
which was slower than its Western allies in ordering and approving
the vaccines,
and it has raised tensions between the bloc and the U.K. and the U.S.

This could pose a challenge to BioNTech's alliance.

Its vaccine uses sophisticated new techniques that require scarce ingredients and expertise.

This makes for a delicate supply chain that is vulnerable to the type
of export controls the EU,
the U.K. and
the U.S. have imposed in recent months, company officials have warned.

Pfizer and BioNTech developed the first Covid-19 vaccine authorized
in the West in record time,
but its complex manufacturing has left the U.S. giant struggling to
meet production targets.

BioNTech's response: An alliance designed to jolt production of
the vaccine and speed up vaccinations in Europe and elsewhere.

The negotiations for the new manufacturing alliance were coordinated with Pfizer, according to a BioNTech spokeswoman.

The cancer-research firm, based in the small German town of Mainz,
came up with the vaccine based on the innovative messenger RNA technology in February 2020,
and then teamed up with Pfizer to test, produce and market it around
the globe.

The vaccine was authorized in Europe and the U.S. in December a
fter trials showed it was highly effective at preventing infections
in adults.

On Thursday, a real-life study by Israel showed that the shot was also 94% successful in stopping asymptomatic transmission.

Yet despite their successes,
Pfizer and BioNTech have struggled to make enough of the vaccine to satisfy demand,
causing growing frustration around the world at the pace of delivery -- a bottleneck BioNTech's new manufacturing alliance now aims to alleviate.

After months of negotiations, the company has now assembled a web
of companies, most of them in Europe and some key rivals to Pfizer.

BioNTech said it was confident the alliance would allow it and Pfizer
to meet their goal of producing two billion doses in 2021.

Under their original agreement,
BioNTech,
which owns the marketing rights for the vaccine,
supplies Germany,
China and
Turkey,
while Pfizer covers the rest of the world.

So far, BioNTech and Pfizer have sold 500 million doses to the EU,
300 million to the U.S.,
120 million to Japan,
110 million to China and its territories,
40 million to the U.K. and 20 million to Canada.

Millions of doses have also been sold in undisclosed contracts
with Middle Eastern and other countries,
and 40 million have been sold to Covax, an international initiative to provide vaccines to developing countries.

Demand is set to keep growing.

Pfizer, a company going back nearly two centuries that employs
around 100,000 people, currently makes 50% of the active ingredient
for all doses, a spokeswoman said,
with the other half produced by medium-size BioNTech.

A BioNTech spokeswoman said the company was in fact producing 60% of the output.

BioNTech's co-founder and chief executive, Ugur Sahin,
told The Wall Street Journal he realized last fall that his partnership with Pfizer wouldn't marshal enough capacity to meet global demand.

Pfizer, which had no mRNA production capacity before its deal with BioNTech,
took longer than expected to set up plants at its sites in Kalamazoo, Mich., and
Puurs,
Belgium, according to the companies.

A Pfizer spokeswoman blamed the delays on the need to put together a supply chain for raw materials,
adding that the company had since scaled up production at an unprecedented pace.

In October, Dr. Sahin and other BioNTech executives opened
negotiations with other companies,
weeks before Pfizer and BioNTech released the final data from their final-stage trials showing that the vaccine was more than 90%
effective in preventing infections.

Days later, the companies quietly notified authorities in the U.S.
and elsewhere that they would slash the delivery target for 2020 from 100 million to just 50 million.

For the U.S., this meant that Pfizer would deliver only 20 million instead of 40 million doses by December.

The Kalamazoo factory was meant to supply the U.S.
while the Puurs site would cater to the rest of the world.

Still, some of the initial 20 million doses that the company supplied to the U.S. came from Europe, according to the companies.

In January, Pfizer launched a major upgrade of its Puurs facility.

The upgrade paused production for two weeks, worsening Europe's vaccine shortage
and prompting some governments to threaten Pfizer with legal action.

Sierk Poetting, BioNTech's chief operating officer,
said the experience had demonstrated to BioNTech the urgency of launching a new manufacturing alliance,
in order to live up to commitments in Europe and other markets.

BioNTech is increasing its own production.

Its German factory,
expected to come on line in April, should produce 750 million doses a year.

The facility will mainly supply the EU,
but its output won't be enough, so BioNTech had to enlist new partners across the supply chain, said Mr. Poetting.

The BioNTech-Pfizer vaccine uses mRNA packaged in a microscopic ball
of fat to elicit an immune response.

Such vaccines can be produced faster than conventional shots,
but the process is sophisticated, with new partners now involved at
each step of the process.

The mRNA is first produced, then purified, concentrated and filtered.

BioNTech has brought in German company Rentschler Biopharma SE to
help with these steps.

Swiss company Novartis is also negotiating a contract to produce DNA molecules used in the first step.

In the next step, the mRNA is encased in its fatty envelope.

The lipids are supplied by the German firms Merck and Evonik Industries AG,
while Austria's Polymun Scientific Immunbiologische Forschung GmbH, Canada's Acuitas Therapeutics Inc.,
and Germany's Dermapharm Holding SE are helping with the formulation.

During the final step, the solution is filtered again and filled into vials,
a process known as finish and fill.

This will be done by Delpharm SAS, a French company; Siegfried AG; Baxter Oncology GmbH from Germany; Novartis, Dermapharm and Sanofi.

BioNTech's European alliance will produce about half of the global active ingredient supply for the Covid-19 vaccine,
and it will cover around 20% of the finish and
fill for each dose, Mr. Poetting said.

While BioNTech is confident the alliance will allow it to meet demand, the number of partners,
the complexity of the process,
and the raw materials required
-- from DNA to enzymes,
salts,
sugars and various lipids
-- make the supply chain delicate, with many opportunities for bottlenecks.

Right now, the scarcest ingredients are the lipids used to deliver
the vaccine's RNA.

These are produced by a handful of companies and the shortage is compounded by the fact that vaccine-makers use a similar technology
and rely on the same suppliers.

"This is the ultimate bottleneck at the moment...
the lipids are the hand-to-mouth issue," Mr. Poetting said.

Write to Bojan Pancevski at [e-mail]


(END) Dow Jones Newswires

March 13, 2021 08:14 ET (13:14 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

[mick]

good morning 03-14-2021 happy sunday , we pray

[mick]

good morning my friend 03-17-2021 happy saint patrick's day & to all have ah party

[-chart]investorshub.advfn.com/images/ihlogo_stpatrick.gif[/chart]

[mick]

$OPK Current Report Filing (8-k)
March 17 2021 - 04:10PM
Edgar (US Regulatory)

https://ih.advfn.com/stock-market/NASDAQ/opko-health-OPK/stock-news/84607024/current-report-filing-8-k


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2021
OPKO Health, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware 001-33528 75-2402409 (State or Other Jurisdiction
of Incorporation) (Commission
File Number) (IRS Employer
Identification No.)
4400 Biscayne Blvd. Miami, Florida 33137 (Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: [phone]
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share OPK NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?



ITEM 1.01.
Entry into a Material Definitive Agreement.
On March 12, 2021, a wholly owned subsidiary of OPKO Health, Inc. (the “Company”), Bio-Reference Laboratories, Inc., a New Jersey corporation (“BRLI”), and certain of its subsidiaries entered into an amendment (the “Amendment”) to that certain Credit Agreement dated as of November 5, 2015 (as amended, the “Credit Agreement”), by and among BRLI, certain of its subsidiaries from time to time party thereto, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent for the lenders. Pursuant to the Amendment, letters of credit, including renewals and extensions, may extend past the maturity date for the Credit Agreement, which is November 5, 2021, subject to certain conditions, including the posting of cash collateral. The Amendment additionally incorporates certain new electronic signature requirements applicable to the Credit Agreement. Except as described in this Current Report on Form 8-K, the other terms of the Credit Agreement remain unchanged.
The foregoing descriptions of the Credit Agreement and the Amendment are only summaries and are qualified in their entirety by references to the complete text of the Credit Agreement and the Amendment. A copy of the Credit Agreement was filed with the Company’s Annual Report on Form 10-K as Exhibit 10.23, filed with the Securities and Exchange Commission on February 29, 2016, and incorporated herein by reference. A copy of the Amendment is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.
ITEM 9.01.
Financial Statements and Exhibits.

(d) Exhibits
Exhibit No. Description 10.1 Amendment No. 12 to Credit Agreement, dated as of March 12, 2021, by and among BioReference Laboratories, Inc., certain of its subsidiaries, and JPMorgan Chase Bank, N.A. 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document




Exhibit Index
Exhibit No. Description 10.1
Amendment No. 12 to Credit Agreement, dated as of March 12, 2021, by and among BioReference Laboratories, Inc., certain of its subsidiaries, and JPMorgan Chase Bank, N.A.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OPKO Health, Inc.
By:
/s/ Steven D. Rubin
Date: March 17, 2021
Name:
Steven D. Rubin
Title:
Executive Vice President - Administration

[mick]

$OPK Pfizer, OPKO Health's somatrogon application validated in Europe
Feb. 26, 2021 8:38 AM ETPfizer Inc. (PFE)By: Mamta Mayani, SA News Editor8 Comments
The European Medicines Agency has validated for review Pfizer (NYSE:PFE) and OPKO Health's (NASDAQ:OPK) marketing authorization application (MAA) for somatrogon, a long-acting recombinant human growth hormone for the treatment of pediatric patients with growth hormone deficiency (GHD).
European Commission decision is expected in 2022.
The submission is supported by the results of a Phase 3 trial evaluating the safety and efficacy of somatrogon administered once-weekly to pediatric patients with GHD.
In 2014, Pfizer and OPKO inked agreement for the development of somatrogon for the treatment of GHD.
Recently in January, the FDA accepted for filing the initial BLA for somatrogon with a target PDUFA action date of October 2021.
OPK shares up 5% premarket.
See all stocks on the move »

https://seekingalpha.com/news/3667118-pfizer-opko-healths-somatrogon-application-validated-in-europe?utm_source=advfn.com&utm_medium=referral

[mick]

good read $PFE $BNTX

$PFE Pfizer vaccine gets final OK in Japan, with rollout to begin this week

https://www.japantimes.co.jp/?post_type=news&p=2920118

[mick]

GOOD MORNING 03-19-2021